The complaint filed Thursday in the US District Court for the District of Delaware accuses BillionToOne of infringing US Patent Nos. 10,612,096, 12,139,760, and 12,435,373, which cover determining the fraction of fetal genetic material in pregnant women’s blood and identifying genetic variations in DNA mixtures.
The patents relate to methods used in non-invasive prenatal testing that can screen for chromosomal abnormalities and genetic disorders.
Illumina’s lawsuit targets BillionToOne’s UNITY prenatal screening tests, which it says ...